Biotech | Pharma Company | Type/Product Area | Amount | Terms/Details (Month) |
Company** | (Symbol/Country) | |||
(Country) | ||||
Abgenix Inc. | Schering-Plough | Collaborative research | ND | Schering-Plough has option to |
(subsidiary of | Research Institute | agreement; use of Abgenix's | enter research and license agree- | |
Cell Genesys Inc.) | (unit of Schering- | XenoMouse technology | ment under which Abgenix would | |
Plough Corp.; | to generate fully human | get additional research and mile- | ||
NYSE:SGP) | monoclonal antibodies to | stone payments as well as royalties | ||
an undisclosed Schering- | (2/98) | |||
Plough target antigen | ||||
Advanced Polymer | Pharmacia & | Agreement to use | ND | Pharmacia & Upjohn will fund all |
Systems Inc. | Upjohn Inc. | Advanced Polymer's | product development, conduct | |
(NYSE:PNU; U.K.) | Microsponge system to | clinical trials and commercialize | ||
develop a topical formula- | product worldwide; Advanced | |||
tion of one of Pharmacia | Polymer gets R&D funds, license | |||
& Upjohn's therapeutics | fees, milestones and royalties (1/98) | |||
Alkermes Inc. | The R.W. Johnson | Agreement to develop | $30M | Alkermes gets $30M in develop- |
Pharmaceutical | injectable, sustained- | ment funds and milestones; John- | ||
Research Institute | release formulation of | son & Johnson gets worldwide | ||
(unit of Johnson | erythropoietin via | commercial rights; Alkermes gets | ||
& Johnson; NYSE:JNJ) | Alkermes' ProLease | milestones; Alkermes will manu- | ||
drug delivery technology; | facture commercial product; John- | |||
product for use in non- | son & Johnson will conduct clini- | |||
dialysis indications to | cal trials and get regulatory appro- | |||
restore blood cell levels | vals (1/98) | |||
in kidney patients | ||||
Alza Corp. | Janssen Pharma- | Collaborative agreement | ND | Alza will fund product develop- |
ceutica NV | to use Alza's E-Trans | ment for next 2 years; Janssen has | ||
(Belgium; unit | drug delivery technology | limited option to fund development | ||
of Johnson & | (uses electric current to | after that point; if it exercises option, | ||
Johnson; NYSE:JNJ) | administer drug through | Janssen will market product and | ||
the skin) with a fentanyl | Alza will share profits in U.S. and | |||
drug product for | get royalties elsewhere; Alza has | |||
treating chronic pain | right to copromote in U.S.; if Janssen | |||
does not exercise option, Alza retains | ||||
all rights to develop and commercial- | ||||
ize product worldwide (1/98) | ||||
Bio-Technology | Swiss Serum and | Development and | ND | Agreement covers scale-up and |
General Corp. | Vaccine Institute | licensing agreement on | optimization of vaccine manufac- | |
(Switzerland) | Bio-Technology Gen- | turing process as well as clinical | ||
eral's 3rd-generation | development, registration and | |||
recombinant hepatitis | marketing of product; companies | |||
B virus vaccine (viral | also will develop combination | |||
surface antigens S, | vaccines; Swiss Serum will buy | |||
pre-S1 and pre-S2 | vaccine from Bio-Technology | |||
expressed in mamma- | General and distribute in western | |||
lian cells) | Europe, Latin America and other | |||
countries; Bio-Technology General | ||||
gets milestones and royalties (2/98) | ||||
Cantab | Kaketsuken | Research and option | ND | Kaketsuken will fund research at |
Pharmaceuticals | (Japan) | agreement to develop | Cantab for 2 years in return for | |
plc (U.K.) | Cantab's DISC VSV | option to license all product rights | ||
virus (genetically | for Japan and certain other Asian | |||
disabled live Varicella | territories; once research phase is | |||
zoster virus) as pro- | completed, parties will form devel- | |||
phylactic vaccine for | opment and marketing agreement, | |||
chickenpox and shingles | under which Cantab will get license | |||
and milestone fees and royalties and | ||||
retain marketing and sublicensing | ||||
rights for rest of world (1/98) | ||||
Chiron Corp. | Pharmacia & | Strategic collaboration | ND | Chiron gets up-front payment; |
Upjohn Inc. | to identify small mole- | companies will contribute equal | ||
(NYSE:PNU; U.K.) | cule inhibitors of | resources and funding for all | ||
hepatitis C virus (HCV) | phases of product development; | |||
companies will share worldwide | ||||
marketing rights; Chiron will pro- | ||||
vide its scientific expertise on | ||||
HCV and nonexclusive rights to | ||||
all HCV targets covered by its | ||||
patents and patent applications | ||||
(2/98) | ||||
Chiroscience | Bristol-Myers | Research and licensing | ND | 3-year agreement; Bristol-Myers |
Group plc (U.K.) | Squibb Co. | agreements on use of | gets worldwide license on D2163 | |
(NYSE:BMY) | matrix metalloproteinase | and D1927; Chiroscience gets | ||
(MMP) inhibitors for | access fees, research funds, mile- | |||
treating cancer; includes | stone payments and royalties; | |||
Chiroscience's 2nd-gen- | Bristol-Myers gets all rights to new | |||
eration oral compounds | and jointly selected MMP inhib- | |||
D2163 (currently in U.K. | itors that are developed for oncol- | |||
Phase I trials) and D1927; | ogy; Chiroscience retains rights | |||
also covers discovery of | in all other therapeutic areas (2/98) | |||
new MMP inhibitors via | ||||
Chiroscience's gene | ||||
expression technology | ||||
Chrysalis | OrthoLogic Corp. | Option on license for | $0.8M | OrthoLogic acquired minority |
BioTechnology | (NASDAQ:OLGC) | Chrysalis' synthetic | (equity; | equity stake in Chrysalis for $0.75M; |
Inc.* | 23-amino-acid-peptide | % ND) | OrthoLogic has 9-month option on | |
chrysalin for orthopedic | worldwide exclusive license to ortho- | |||
applications, initially | pedic applications of chrysalin; Ortho- | |||
for healing of fractures | Logic can continue and expand option | |||
contingent on preclinical results; | ||||
OrthoLogic will fund R&D, mile- | ||||
stones and clinical trials (1/98) | ||||
Chrysalis | Pfizer Inc. | Genomics-based trans- | ND | Chrysalis will use its high-capacity |
International Corp. | (NYSE:PFE) | genic research contract | transgenic animal capabilities to | |
and its wholly owned | and collaboration to | identify and validate new thera- | ||
subsidiary, | identify and validate new | peutic targets from genetic data | ||
Chrysalis DNX | therapeutic targets for 2 | generated by Pfizer's genomics | ||
Transgenic | major disease categories | initiative; Pfizer will fund research | ||
Sciences | via Chrysalis' transgenic | for 2 years (1/98) | ||
mouse and rat lines | ||||
CytoMed Inc.* | UCB Pharma | Research collaboration | ND | UCB will fund joint research pro- |
(division of UCB | on therapeutics for | gram; further details ND (3/98) | ||
Group; Belgium) | major inflammatory | |||
diseases (via small | ||||
molecules that modulate | ||||
specific anti-inflam- | ||||
matory activities) | ||||
deCode Genetics | F. Hoffmann- | Collaboration to dis- | $200M | 5-year collaboration; deCode gets |
Inc.* (Iceland) | La Roche Ltd. | cover disease genes | (equity; | up to $200M (including equity |
(Switzerland) | for use in therapeutics | % ND) | investment, research funds and | |
and diagnostics; use of | milestone payments); Roche gets | |||
Icelandic population data- | rights to develop small molecule | |||
base to discover genes | drugs and drugs based on gene | |||
that predispose people | products as well as diagnostics; | |||
to developing 12 | deCode retains rights to gene and | |||
common diseases | antisense therapies (2/98) | |||
(4 cardiovascular; 4 | ||||
psychiatric/neurologic; | ||||
4 metabolic); collab- | ||||
oration also includes | ||||
pharmacogenomics | ||||
component | ||||
DepoMed Inc. | The R.W. Johnson | Research collaboration | ND | ND (3/98) |
Pharmaceutical | on use of DepoMed's | |||
Research Institute | Gastric Retention Sys- | |||
(unit of Johnson & | tem (orally administered, | |||
Johnson; NYSE:JNJ) | controlled-release system) | |||
with a Johnson & Johnson | ||||
drug | ||||
Elan | Novartis Pharma- | Development and | $18M | Elan will reformulate Novartis' |
Pharmaceutical | ceuticals Corp. | licensing agreement on | drug and test its pharmacokinetics | |
Technologies | (unit of Novartis | use of Elan's extended- | in human trials; Novartis will con- | |
(division of Elan | AG; Switzerland) | release drug delivery | duct all other clinical trials and | |
Corp. plc; Ireland) | technology with a | product registrations; Elan gets | ||
Novartis prescription | development and licensing fees of | |||
drug (not disclosed) | $18M total, as well as royalties; | |||
Elan will manufacture product for | ||||
Novartis and gets manufacturing | ||||
fees (1/98) | ||||
Solvay Pharma- | Agreement on use of | ND | Elan will develop new dosage | |
ceuticals Inc. | Elan's extended-release | formulation of Luvox; Solvay will | ||
(member of | drug delivery technology | conduct all clinical trials and pro- | ||
The Solvay Group; | with Solvay's prescrip- | duct registrations; Elan gets dev- | ||
Belgium) | tion drug Luvox (flu- | elopment and licensing fees as | ||
voxamine; a selective | well as milestones; Elan will manu- | |||
serotonin reuptake | facture new formulation and gets | |||
inhibitor for treating | manufacturing fees; Elan also gets | |||
obsessive compulsive | royalties (2/98) | |||
disorder and depression) | ||||
Epix Medical Inc. | Mallinckrodt Inc. | Collaboration to improve | ND | Companies will develop hardware |
(NYSE:MKG) and | and expand capabilities | and software to be used with Epix's | ||
General Electric | of magnetic resonance | MS-325 injectable contrast agent; | ||
Medical Systems | imaging for diagnosing | financial details ND (1/98) | ||
(NYSE:GE) | coronary artery disease | |||
and peripheral vascular | ||||
disease | ||||
Ergo Science | The R.W. Johnson | Collaboration to | $40M | Ergo gets $10M license fee plus |
Corp. | Pharmaceutical | develop Ergoset | (equity; | $10M equity investment; Ergo |
Research Institute | (bromocriptine mes- | % ND) | also gets $20M on FDA approval | |
and Ortho-McNeil | ylate, dopamine agonist) | of Ergoset for Type II diabetes; | ||
Pharmaceutical Inc. | and other products as | companies will share equally costs | ||
(units of Johnson | treatments for Type II | of developing and commercializ- | ||
& Johnson; NYSE:JNJ) | diabetes and obesity | ing Ergoset and other products; | ||
(NDA accepted for | they also will share profits equally; | |||
filing 10/97) | Ergo gets royalties on sales outside | |||
U.S.; Ergo gets additional mile- | ||||
stones for other products; agree- | ||||
ment subject to antitrust consider- | ||||
ations (2/98) | ||||
Gene Logic Inc. | NV Organon (unit | Gene expression data- | ND | 3-year agreement; Organon gets |
of Akzo Nobel; | base alliance; use of | nonexclusive access to database | ||
the Netherlands) | Gene Logic's Normal | and bioinformatics system for use | ||
database (reference set | in its internal drug discovery pro- | |||
of quantitative gene | gram; Gene Logic also will con- | |||
expression profiles in | struct gene expression database | |||
mouse, rat and human | exclusively for Organon; Organon | |||
tissues) and its bio- | responsible for worldwide devel- | |||
informatics system for | opment and commercialization of | |||
analysis and integration | therapeutics; Gene Logic retains | |||
of gene expression data | rights to diagnostics and certain | |||
therapeutics; Gene Logic gets | ||||
research funds, license fees, mile- | ||||
stones and royalties (1/98) | ||||
Genentech Inc. | Dako A/S | Agreement to develop | ND | Dako gets license to develop |
(Denmark) | in vitro diagnostic kit | immunohistochemical diagnostic | ||
for screening breast | kit; Genentech gets royalties; | |||
cancer patients for | further details ND (3/98) | |||
overexpression of | ||||
HER2 (growth factor | ||||
receptor) and to identify | ||||
their potential eligibility | ||||
to be treated with | ||||
Herceptin (humanized | ||||
anti-HER2 monoclonal | ||||
antibody; Phase III trials | ||||
completed) | ||||
Genentech Inc. | Pharmacia & | Development and | $35M | Pharmacia & Upjohn gets exclu- |
Upjohn Inc. | licensing agreement on | sive worldwide rights to TPO; | ||
(NYSE:PNU; U.K.) | Genentech's thrombo- | companies will jointly develop | ||
poietin (TPO) for treat- | product; Genentech will manufac- | |||
ing thrombocytopenia | ture product for development | |||
in cancer patients | work and commercialization; | |||
receiving chemotherapy | Pharmacia & Upjohn will fund | |||
and in stem cell trans- | future development costs and pay | |||
plants (currently in | $35M in license fees through | |||
Phase II trials) | 2000 (including initial $12M fee); | |||
if product approved for market- | ||||
ing, Genentech gets final transfer | ||||
payment and royalties; Genentech | ||||
will conduct clinical trials in myelo- | ||||
ablative therapy; Pharmacia & | ||||
Upjohn will conduct clinical trials | ||||
for all other indications (1/98) | ||||
Genzyme | Merck & Co. Inc. | License agreement on | $8M | Merck gets nonexclusive rights to |
Molecular | (NYSE:MRK) | Genzyme Molecular's | cancer assay methods; Genzyme | |
Oncology | methods for screening | Molecular gets up-front payment | ||
(division of | small molecule com- | and $8M in milestones, as well as | ||
Genzyme Corp.) | pounds that inhibit | royalties on sales of any thera- | ||
binding of cancer- | peutic products (2/98) | |||
related protein MDM2 | ||||
to the p53 protein | ||||
(binding prevents p53 | ||||
from activating genes | ||||
that control cell | ||||
division) | ||||
Schering-Plough | Research and option | $80M | Schering-Plough has option to | |
Corp. (NYSE:SGP) | agreement; use of | exclusively license Genzyme Mol- | ||
Genzyme Molecular's | ecular's gene delivery systems for | |||
lipid gene delivery | use with 6 of its genes; if it exer- | |||
systems with several of | cises option, Genzyme Molecular | |||
Schering-Plough's genes, | gets license fees, research funding | |||
including p53 tumor | and milestones totaling $80M; | |||
suppressor gene, to | Genzyme Molecular gets $7M | |||
develop gene therapy | over next year for research on p53 | |||
products | gene therapy product (1st of 6 | |||
genes); Genzyme Molecular also | ||||
gets royalties on sales (1/98) | ||||
Immusol Inc.* | Pfizer Inc. | Genomic-based research | ND | Immusol will design specific |
(NYSE:PFE) | collaboration to validate | ribozymes for each candidate gene | ||
therapeutic targets in | target sequence of Pfizer; further | |||
Pfizer's pipeline via | details ND (3/98) | |||
Immusol's hairpin | ||||
ribozyme technology | ||||
and in vivo assay model | ||||
to determine gene func- | ||||
tion in human cell lines | ||||
Inhale Therapeutic | Eli Lilly and Co. | Collaboration on use | $20M | Inhale gets $20M in R&D funds |
Systems | (NYSE:LLY) | of Inhale's deep-lung | and milestones; Lilly gets world- | |
delivery system for | wide rights to formulated drug; | |||
macromolecules to | Inhale gets royalties; Inhale will | |||
formulate an unspeci- | manufacture packaged powders | |||
fied protein drug for | for and supply inhalation devices | |||
Lilly | to Lilly; Lilly responsible for clini- | |||
cal trials, product registration and | ||||
marketing (1/98) | ||||
Integra | Johnson & Johnson | Strategic alliance on | $12M | Integra gets $12M in milestones; |
LifeSciences Corp. | Professional Inc. | an absorbable, collagen- | Johnson & Johnson will fund all | |
(subsidiary of | based implant (combined | development costs beyond pre- | ||
Johnson & Johnson; | with an RGD peptide) for | clinical stage; Integra will manu- | ||
NYSE:JNJ) | repairing and regenerating | facture product; Johnson & John- | ||
articular cartilage | son will develop arthroscopic | |||
instrumentation to be used in | ||||
surgeries; Johnson & Johnson gets | ||||
worldwide marketing rights (2/98) | ||||
Intercardia Inc. | Opocrin SpA | Letter of intent to | ND | Intercardia will get worldwide |
(Italy) | license OP2000 (an | license except in Japan and | ||
oligosaccharide product | South Korea; Intercardia will | |||
derived from heparin | conduct clinical trials; Opocrin | |||
with antithrombotic and | will get $1M on signing of defin- | |||
anti-inflammatory pro- | itive agreement (3/98) | |||
perties) for treating | ||||
inflammatory bowel | ||||
disease | ||||
Ligand | SmithKline | Collaboration on small | $9M | SmithKline will buy 0.27M shares |
Pharmaceuticals | Beecham plc | molecule drugs that | (equity; | Ligand common stock for $5M |
Inc. | (NYSE:SBH; U.K.) | modulate signaling | % ND) | ($18.22/share, premium to market) |
pathway controlled by | and will also pay $1M for a 5- | |||
leptin; use of Ligand's | year warrant to buy 0.15M shares | |||
STATS technology | at $20/each; SmithKline will buy | |||
(signal transduction and | more stock on achievement of one | |||
activator of transcription) | specific milestone and will pay | |||
to develop oral drugs | cash for subsequent milestones; | |||
for treating or prevent- | SmithKline gets exclusive world- | |||
ing obesity | wide rights to products; Ligand | |||
gets royalties; subject to anti- | ||||
trust considerations (3/98) | ||||
Magainin | Ambalal Sarabhai | Memorandum of under- | ND | Magainin will license applicable |
Pharmaceuticals | Enterprises Ltd. | standing to form a joint | technology to the joint venture and | |
Inc. | (India) | venture in India to | provide technical assistance; | |
develop and commer- | Sarabhai will conduct and fund all | |||
cialize certain magainin | development and commercializa- | |||
peptide compounds | tion activities for the joint venture; | |||
(including Cytolex | Magainin and Sarabhai will share | |||
[a.k.a. MSI-78]) for | profits equally (1/98) | |||
treating infection in | ||||
diabetic foot ulcers as | ||||
well as other indications | ||||
Medarex Inc. | Schering AG | Research collaboration | $9M | Medarex gets R&D payments, |
(Germany) | and license agreement; | license fee and milestones totaling | ||
use of Medarex' HuMAb- | $9M, plus royalties (2/98) | |||
mouse technology to | ||||
make fully human mono- | ||||
clonal antibodies to a | ||||
Schering antigen | ||||
Molecular | Rhone-Poulenc | DNA microarray tech- | ND | Rhone-Poulenc Rorer will provide |
Dynamics Inc. | Rorer Inc. (sub- | nology access agreement; | funding and technical expertise; | |
and Amersham | sidiary of Rhone- | collaboration for contin- | it gains early access to integrated | |
Pharmacia | Poulenc SA; NYSE: | ued development of new | microarray systems; further details | |
Biotech (Sweden) | RP; France) | microarray technologies | ND (1/98) | |
NanoSystems | Boehringer | Development, license | ND | NanoSystems gets up-front license |
LLC* | Ingelheim GmbH | and supply agreement; | fee, milestone payments and | |
(Germany) | use of NanoCrystal | royalties; further terms ND (2/98) | ||
technology (improves | ||||
delivery of poorly | ||||
water-soluble drugs) | ||||
for undisclosed com- | ||||
pound for respiratory | ||||
delivery | ||||
Oncor Inc. | Becton Dickinson | Licensing agreement | ND | Oncor gets license fees, research |
& Co. (NYSE:BD) | for Oncor's Sunrise | funding, milestones and royalties | ||
Detection System; to | (3/98) | |||
be used in conjunction | ||||
with Becton's Strand | ||||
Displacement Ampli- | ||||
fication technology | ||||
in kits for infectious | ||||
disease detection | ||||
OncorMed Inc. | Schering-Plough | OncorMed will provide | ND | OncorMed will analyze patient |
Research Institute | p53 pharmacogenomic | samples (to identify those with | ||
(unit of Schering- | services for Schering- | missing or defective p53 gene) for | ||
Plough Corp.; | Plough's clinical trials | Schering-Plough's clinical trials; | ||
NYSE:SGP) | of its rAd/p53 cancer | OncorMed also will provide se- | ||
gene therapy (to ascertain | quencing and other services (1/98) | |||
p53 status of prospective | ||||
clinical trial subjects) | ||||
Oxford Asymmetry | Bayer AG | Development of lead | $26M | 2-year collaboration; Bayer will |
International plc | (Germany) | discovery libraries of | screen Oxford's libraries for leads; | |
(LSE:OAI; U.K.) | new chemical entities | Oxford gets $14.6M over 2 years, | ||
(via Oxford's combi- | plus $11.4M in milestones for | |||
natorial chemistry) as | each product that completes clini- | |||
product candidates for | cal trials; Oxford also gets royal- | |||
Bayer's pharmaceutical, | ties (2/98) | |||
animal health and crop | ||||
protection businesses | ||||
Oxford Biomedica | Rhone-Poulenc | Feasibility study on | ND | ND (1/98) |
plc (LSE:OXB; U.K.) | Rorer Inc. (sub- | use of Oxford's lenti- | ||
sidiary of Rhone- | viral vector systems | |||
Poulenc SA; NYSE: | in Rhone-Poulenc | |||
RP; France) | Rorer's functional | |||
genomics program (to | ||||
transfer genes to certain | ||||
non-dividing tissues) | ||||
PowderJect | Glaxo Wellcome | Collaboration, develop- | $321M | Glaxo gets exclusive worldwide |
Pharmaceuticals | plc (NYSE:GLX; U.K.) | ment, license and option | (7.7% | rights to use PowderJect technol- |
plc (U.K.) | agreement on DNA vac- | equity) | ogy to commercialize prophylac- | |
cines using PowderJect | tic HBV vaccine and options | |||
technology (includes pro- | on others; Glaxo will take over | |||
phylactic hepatitis B | development of prophylactic HBV | |||
virus (HBV) DNA vac- | vaccine, for which it will pay $4M | |||
cine, HBV and HIV DNA | license fee; Glaxo also will buy | |||
vaccines, DNA vaccines | $20M of equity (4.9M shares for | |||
for 2 infectious diseases | a 7.71% stake) and pay another | |||
and others); technology | $297M in milestones, research | |||
based on DNA-coated | funding and license fees as it exer- | |||
gold particles delivered | cises its options on the other vac- | |||
via needleless injection | cines; Glaxo will be responsible | |||
(prophylactic HBV | for all vaccine development and | |||
vaccine in clinical trials) | commercialization; PowderJect | |||
gets royalties; PowderJect will | ||||
manufacture and supply its device; | ||||
5-year agreement subject to anti- | ||||
trust considerations (3/98) | ||||
Progenics | Roche Discovery | Collaboration on orally | ND | Roche gets exclusive worldwide |
Pharmaceuticals | Welwyn (U.K.; | active drugs that target | license to Progenics' HIV co- | |
Inc. | member of The | HIV coreceptors CCR5 | receptor technology; Progenics | |
Roche Group; | and CD4 (required for | gets up-front and milestone pay- | ||
Switzerland) | fusion and infection of | ments, research funding for 3 | ||
immune cells) | years and royalties (1/98) | |||
Protein Design | Eli Lilly and Co. | Collaborative agree- | $15M | Protein Design got $3M in initial |
Labs Inc. | (NYSE:LLY) | ment on antibiotics | fee and gets annual research fund- | |
for treating certain | ing of $2.4M for 5 years; Protein | |||
bacterial infections, | Design also gets milestones and | |||
including those caused | royalties; Lilly gets exclusive | |||
by antibiotic-resistant | worldwide rights to gene targets | |||
strains; use of high- | and human pharmaceutical and | |||
throughput screens | related diagnostic products directed | |||
and combinatorial | to 7 specific genera of bacteria; | |||
chemistry to identify | Protein Design retains rights to | |||
bacterial genes that | targets and compounds related to | |||
are differentially ex- | other bacteria, viruses and fungi; | |||
pressed during infection | parties will negotiate copromotion | |||
rights in U.S. and Canada (1/98) | ||||
RiboGene Inc.* | Dainippon | Collaboration on anti- | $8M | Dainippon gets exclusive world- |
Pharmaceutical | bacterial compounds | (equity; | wide rights to develop and market | |
Co. Ltd. (Japan) | that inhibit or interfere | % ND) | products; RiboGene gets $2M | |
with protein translation | annually for 3 years to fund | |||
in pathogenic bacteria | research; Dainippon also will buy | |||
(will use 2 of Ribo- | $2M in RiboGene equity; Ribo- | |||
Gene's principal bacterial | Gene gets milestone payments for | |||
targets) | each compound, as well as royal- | |||
ties; RiboGene has right to copro- | ||||
mote products in Europe and U.S.; | ||||
RiboGene retains rights to its | ||||
other bacterial targets (1/98) | ||||
Sepracor Inc. | Janssen Pharma- | Collaboration and | ND | Companies will jointly fund prod- |
ceutica NV | license agreement on | uct development; Janssen has op- | ||
(Belgium; unit | 3rd-generation non- | tion to acquire certain rights in U.S. | ||
of Johnson & | sedating antihistamine | and elsewhere; if exercised, com- | ||
Johnson; NYSE:JNJ) | norastemizole (for treat- | panies will share equally costs and | ||
ing seasonal allergic | profits of further development; | |||
rhinitis) | Sepracor retains rights to copro- | |||
mote in U.S.; Janssen has rights | ||||
elsewhere (2/98) | ||||
Sequenom* | Bruker-Franzen | Collaborative agree- | ND | Bruker-Franzen will upgrade the |
Analytik GmbH | ment to develop high- | hardware and software interfaces | ||
(Germany) | speed mass spectrometer | of its instruments to enable them | ||
dedicated to process | to process Sequenom's Spectro- | |||
Sequenom's Spectro- | Chips exclusively (1/98) | |||
Chips for DNA analysis | ||||
(functional microarrays) | ||||
Signal | DuPont Merck | Collaboration on drugs | $25M | 3-year collaboration; DuPont will |
Pharmaceuticals | Pharmaceutical Co. | for hepatitis C and | (equity; | provide research funding, and up-front |
Inc.* | (partnership between | HIV infection; use of | % ND) | and milestone payments; DuPont |
the DuPont Co. | Signal's high-throughput | will buy equity stake in Signal's | ||
[NYSE:DD] and | screening assays to | IPO; Signal will screen for and | ||
Merck & Co. Inc. | identify virus-specific | identify leads; DuPont will opti- | ||
[NYSE:MRK]) | gene-regulating targets | mize leads, and develop and mar- | ||
ket products; Signal gets royalties | ||||
(1/98) | ||||
Nippon Kayaku | Collaboration to | ND | Nippon will provide research fund- | |
Co. Ltd. (Japan) | develop Nippon's small | ing to Signal for 1st 2 years and | ||
molecule nerve growth | will continue to conduct animal | |||
factor mimetic as a drug | pharmacology studies; Signal will | |||
for treating peripheral | optimize compound prior to clin- | |||
neuropathies; use of | ical trials via combinatorial chem- | |||
Signal's human neuronal | istry and neuronal cell lines; com- | |||
cell lines to optimize | panies will co-develop product and | |||
compound and character- | share marketing rights worldwide | |||
ize its mode of action | except Japan (2/98) | |||
Synaptic | Glaxo Wellcome | Licensing agreement | $2M | Synaptic had already licensed |
Pharmaceutical | plc (NYSE:GLX; U.K.) | for certain of Synaptic's | these rights to Merck & Co. under | |
Corp. | alpha adrenergic receptor | an 11/93 agreement; thus Merck | ||
patents and functional- | had to approve the transaction | |||
use patents for treating | with Glaxo; Glaxo gets non-exclu- | |||
benign prostatic hyper- | sive license to receptor patents; | |||
plasia | Synaptic got $2M up front and will | |||
get additional payment if Merck | ||||
exercises option on nonexclusive | ||||
license to functional-use patents | ||||
(option expires 5/22/99); Synaptic | ||||
gets milestones under certain con- | ||||
ditions and royalties (3/98) | ||||
Grunethal GmbH | Cooperative agreement | ND | Grunethal will conduct preclinical | |
(Germany) | to develop drugs for | and clinical studies; Synaptic | ||
treating pain via | retains manufacturing and market- | |||
Synaptic's cloned human | ing rights in U.S., Canada and | |||
receptor-targeted drug | Mexico; Grunethal has those rights | |||
design technology and | in Europe and Central and South | |||
Grunethal's pain model | America; companies will share | |||
systems; initial focus | rights elsewhere; companies are | |||
on alpha-2 adrenergic | each responsible for own expenses | |||
receptors | during research phase and will | |||
share equally all costs through | ||||
Phase II trials (1/98) | ||||
Synt:em* | Laboratoires | Research collaboration | ND | Servier will develop and market |
(France) | Servier (France) | on vectorization of anti- | products; Synt:em gets milestone | |
cancer molecules using | payments; further details ND | |||
Synt:em's Pep:trans | (2/98) | |||
technology (enables | ||||
creation of peptidic | ||||
vectors able to cross | ||||
cell membranes, thus | ||||
internalizing drugs into | ||||
cancer cells) | ||||
Therion Biologics | Pasteur Merieux | Collaboration to | $25M | Cross-licensing agreement; Pasteur |
Corp.* | Connaught | develop live recom- | (equity; | gets exclusive rights to certain of |
(Canada; member | binant pox virus | % ND) | Therion's therapeutic cancer vac- | |
of the Rhone- | vector-based thera- | cines; Therion gets access to cer- | ||
Poulenc Group) | peutic vaccines for | tain of Pasteur's pox virus vector | ||
and its affiliate | colorectal and lung | technologies; Pasteur gets exclu- | ||
Virogenetics | cancer and melanoma | sive worldwide rights to Therion's | ||
Corp.* | therapeutic melanoma vaccines | |||
and carcinoembryonic antigen | ||||
(CEA)-based therapeutic vaccines; | ||||
Therion gets $25M in milestones; | ||||
Pasteur made initial equity invest- | ||||
ment in Therion (1/98) | ||||
Transgene SA | Schering-Plough | Research collaboration | $88M | 5-year collaboration; Schering- |
(France) | Corp. (NYSE:SGP) | and license agreement; | Plough gets rights to existing and | |
use of Transgene's | future adenoviral gene technology | |||
adenoviral gene delivery | for use with p53 gene; Schering- | |||
systems with Schering- | Plough has option to license Trans- | |||
Plough's p53 tumor | gene's adenoviral systems for up | |||
suppressor gene (and | to 5 additional genes; Transgene | |||
several other genes) to | gets $8M in initial license fees; if | |||
develop gene therapy | Schering-Plough exercises options | |||
products | for all 6 genes, Transgene gets | |||
$88M (licensing fees, research | ||||
funding, milestones); Transgene | ||||
also gets royalties (2/98) | ||||
Triangle | Bukwang Pharma- | Licensing of L-FMAU | $6M | Triangle licensed rights to product |
Pharmaceuticals | ceuticals Ind. Co. | (a pyrimidine nucleo- | for all human antiviral applications | |
Inc. | Ltd. (South Korea) | side analogue intended | worldwide except in Korea; Bukwang | |
for treating hepatitis B | gets up-front fee of $6M, milestone | |||
infection) | payments and royalties (2/98) | |||
Vanguard Medica | Stiefel | R&D collaboration | $8M | Vanguard responsible for clinical |
Group plc (U.K.) | Laboratories Inc.* | on VML 262 as a | development through Phase II, at | |
topical treatment for | which point Stiefel will take over | |||
psoriasis (compound was | clinical trials (which it will fund); | |||
originally isolated from | Stiefel gets product rights in Euro- | |||
marigolds and is now | pean Union and Latin America; | |||
chemically synthesized; | Stiefel will reimburse some of | |||
Phase II trials initiated | Vanguard's preclinical develop- | |||
2/98) | ment costs; Vanguard will get $8M | |||
in milestones over 4-5 years, as | ||||
well as royalties (3/98) | ||||
Xenova Group plc | Eli Lilly and Co. | R&D collaboration on | $35M | Xenova and MetaXen will get |
(U.K.) and its sub- | (NYSE:LLY) | small molecule inhib- | $35M in license fees, research | |
sidiary, MetaXen LLC | itors of plasminogen | funding and milestones, as well as | ||
activator inhibitor | royalties; Lilly gets exclusive | |||
(PAI-1) from Xenova's | worldwide rights to PAI-1 inhibit- | |||
natural products library | ors and related technology for use | |||
as antithrombotic drugs | in cardiovascular medicine; Meta- | |||
for chronic use | Xen will conduct preclinical work; | |||
Lilly responsible for clinical trials | ||||
and product registrations as well | ||||
as marketing (2/98) | ||||
NOTES: | ||||
# This chart contains information on new agreements only, covering the time between 1/1/98 and 3/24/98. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the 4/13/98 issue of BioWorld Financial Watch. | ||||
A chart covering modified agreements and terminated agreements between big pharma and biotech companies for the same time period (1/1/98 3/24/98) also will appear in the 4/13/98 issue of BioWorld Financial Watch. | ||||
ND = Not disclosed, reported and/or available; LSE = London Stock Exchange | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 15-16. |
To read more on related topics, click on one of the words below.